LAT1 can be exploited for carrier-mediated drug delivery, for instance with boronophenylalanine in BNCT or with LAT1-selective PET tracers that demonstrate high tumor uptake and favorable tumor-to-background ratios. The gene discussed is SLC7A5; the disease is neoplasm.